Comparison of effect of fasting and of five different diets on the bioavailability of single oral dose of clarithromycin 500 mg extended release tablet

References

• Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999;37:213–255.
   PubMed Web of Science ®Google Scholar
• Shargel L, Wu-pong S, Andrew BC. Applied biopharmaceutics and pharmacokinetics. 5th Ed. NJ, USA: McGraw Hill Medical; 2005. p 391–392.
   Google Scholar
• Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978;3:337–351.
   PubMed Web of Science ®Google Scholar
• Welling PG. Influence of food and diet on GI drug absorption: a review. J Pharmacokinet Pharmacodyn 1977;5:291–334.
   Web of Science ®Google Scholar
• Winstanley PA, Orme MLE. The effects of food on drug bioavailability. Br J Clin Pharm 1989;28:621–628.
   PubMed Web of Science ®Google Scholar
• Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokin 1999;37:385–398.
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992;11:137–152.
   PubMedGoogle Scholar
• Hardy DJ, Guay DRP, Jones RN. Clarithromycin, a unique macrolide: a pharmacokinetic, macrobiological, and clinical overview. Diagn Microbiol Infect Dis 1992;15:39–53.
   PubMed Web of Science ®Google Scholar
• Fernandez PB, Ramer R, Rode RA, Freiberg LA. Bioassay for A-56268 (TE-031) and identification of its major metabolite 14-hydroxy-6- O-methyl erythromycin. Eur J Clin Microbiol Infect Dis 1988;7:73–76.
   PubMed Web of Science ®Google Scholar
• Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991;19:29–37.
   PubMed Web of Science ®Google Scholar
• Barradell LB, Plosker GL, McTavish D. Clarithromycin: a review of its pharmacological properties and therapeutic use in Mycobacterium aviumintracellulare complex infection in patients with acquired immunodeficiency syndrome. Drugs 1993;46:289–312.
   PubMed Web of Science ®Google Scholar
• Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989;33:1531–1534.
   PubMed Web of Science ®Google Scholar
• Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Chevret S, Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with acquired immune deficiency syndrome. Am Rev Respir Dis 1991;144:564–569.
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121:905–911.
   PubMed Web of Science ®Google Scholar
• Hardy DJ, Swanson RN, Rode RA., Marsh M., Shipkowitz NL, Clement JJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990;34:1407–1413.
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, Maher LA, Howell AW. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. Antimicrob Agents Chemother 1991;35:1524–1526.
   PubMed Web of Science ®Google Scholar
• Biaxin XL. [package insert]. North Chicago, IL:Abbott Laboratories; 2007.
   Google Scholar
• Guay DR, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olson CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001;23:566–577.
   PubMed Web of Science ®Google Scholar
• Gaete LG, Schatloff OB, Anziani FO, Serrano CA, Ceballos VN, Bello PMP, Ortiz MO, Saavedra IS, Yatabe YR. Bioequivalence of two formulations of modified-release clarithromycin available in the Chilean market [in Spanish]. Rev Chil Infectol 2003;20:171–177.
   Google Scholar
• Cheng LK, Nafziger NA, Peloquin AC, Amsden WG. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrobial Agents Chemo 1998;42:927–929.
   PubMed Web of Science ®Google Scholar
• Chu S, Park Y, Locke C, Wilson DS, Cavanaugh JC. Drug food interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1992;32:32–36.
   PubMed Web of Science ®Google Scholar
• Alkhalidi AB, Tamimi JJ, Salem II, Ibrahim H, Sallam IAA, Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers. Clin Therap 2008;30:1831–1843.
   PubMed Web of Science ®Google Scholar
• The United States Pharmacopeia and National Formulary–USP 26 NF 21. Rockville, MD: US Pharmacopoeial Convention; 2003.
   Google Scholar
• Gurule S, Verma PRP, Monif T, Khuroo A, Partani P. Sensitive liquid chromatographic determination of clarithromycin and 14-hydroxy clarithromycin in human plasma with tandem mass spectrometry. J Liq Chromatog Relat Technol 2008;31:2955–2973.
   Web of Science ®Google Scholar
• Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products–general considerations. Revision 1. March 2003. Available online at: http://www. fda.gov/cder/guidance/5356fnl.htm, accessed September 17, 2008.
   Google Scholar
• Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002;62:1481–1502.
   PubMed Web of Science ®Google Scholar
• Thiessen JJ. Bioavailability and bioequivalence (Chapter 8). Toronto, Canada:University of Toronto.
   Google Scholar
• Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008;60:717–733.
   PubMed Web of Science ®Google Scholar
• Mckellars QA, Brunid F, Jones G. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther 2004;27:503–514.
   PubMed Web of Science ®Google Scholar